ICU Medical, Inc. $ICUI Shares Sold by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. lessened its stake in ICU Medical, Inc. (NASDAQ:ICUI) by 4.5% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 19,364 shares of the medical instruments supplier’s stock after selling 905 shares during the period. Envestnet Asset Management Inc. owned about 0.08% of ICU Medical worth $2,559,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in ICUI. State of New Jersey Common Pension Fund D lifted its stake in ICU Medical by 19.3% during the 2nd quarter. State of New Jersey Common Pension Fund D now owns 14,407 shares of the medical instruments supplier’s stock worth $1,904,000 after acquiring an additional 2,335 shares in the last quarter. AlphaQuest LLC increased its stake in ICU Medical by 3,058.3% during the second quarter. AlphaQuest LLC now owns 1,516 shares of the medical instruments supplier’s stock worth $200,000 after purchasing an additional 1,468 shares during the period. Cullen Frost Bankers Inc. acquired a new stake in shares of ICU Medical during the second quarter worth about $38,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of ICU Medical during the second quarter worth about $1,524,000. Finally, William Blair Investment Management LLC purchased a new position in shares of ICU Medical in the second quarter valued at approximately $27,928,000. 96.10% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Wall Street Zen downgraded shares of ICU Medical from a “buy” rating to a “hold” rating in a research note on Saturday. Piper Sandler upped their price objective on ICU Medical from $153.00 to $172.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Raymond James Financial decreased their target price on ICU Medical from $187.00 to $180.00 and set a “strong-buy” rating for the company in a report on Friday, August 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of ICU Medical in a research note on Wednesday, October 8th. Finally, KeyCorp upped their price target on ICU Medical from $173.00 to $175.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $181.75.

ICU Medical Price Performance

ICU Medical stock opened at $136.50 on Monday. The company has a current ratio of 2.44, a quick ratio of 1.17 and a debt-to-equity ratio of 0.63. The company has a fifty day simple moving average of $125.34 and a 200-day simple moving average of $128.27. The stock has a market cap of $3.37 billion, a P/E ratio of -89.80 and a beta of 0.83. ICU Medical, Inc. has a 12-month low of $107.00 and a 12-month high of $175.51.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $2.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.43 by $0.60. The company had revenue of $533.30 million for the quarter, compared to analysts’ expectations of $511.46 million. ICU Medical had a positive return on equity of 7.24% and a negative net margin of 1.56%.ICU Medical’s quarterly revenue was down 8.9% on a year-over-year basis. During the same period last year, the firm earned $1.59 earnings per share. ICU Medical has set its FY 2025 guidance at 7.350-7.650 EPS. Equities analysts expect that ICU Medical, Inc. will post 4.11 EPS for the current fiscal year.

Insider Activity

In related news, VP Virginia Ruth Sanzone sold 930 shares of the stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $142.34, for a total value of $132,376.20. Following the transaction, the vice president directly owned 5,456 shares of the company’s stock, valued at $776,607.04. This trade represents a 14.56% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Elisha W. Finney sold 1,285 shares of the business’s stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $140.42, for a total transaction of $180,439.70. Following the completion of the sale, the director directly owned 3,995 shares of the company’s stock, valued at approximately $560,977.90. This trade represents a 24.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 1.50% of the company’s stock.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.